SLEDAI-2K for 1 year as gold standard. After categorizing moderate to severe ≥ 3 of SLEDAI-2K, sensitivity, specificity, positive predictive values (PPV), and negative predictive values for the algorithms to detect patients with moderate to severe SLE were estimated.

Results We included 151 patients with SLE. Their mean age was 34.5 ± 8.8, and 94.7% were female, presenting initial SLEDAI-2K score of 3.8 ± 3.2. For classifying moderate to severe SLE, the PPV of claims-based algorithm ranged from 75.86 to 77.19%. However, the algorithms modifying glucocorticoid dose to differentiate between moderate and severe SLE or considering any prescriptions of intravenous glucocorticoid did not increase the PPV.

Conclusions The algorithm using diagnostic codes for comorbidities and medications demonstrated PPV of 77.19% to detecting moderate to severe SLE. It may be a useful for classifying SLE severity in Korean claims database studies.

**References**
4. Eun Jin Jang, Yoon-Kyoung Sung. 1Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Republic of Korea; 2Department of Statistics, Kyungpook National University, Republic of Korea; 3College of Pharmacy, Chung-Ang University, Republic of Korea; 4Department of Information Statistics, Andong National University, Republic of Korea

**Background** Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder with various ranges of organ damages, so that patients with SLE might face to considerable medical costs in their early disease courses. We aimed to estimate the progression of direct healthcare costs before and after diagnosis of SLE and to compare healthcare costs by disease severity in Korean patients with SLE.

**Methods** Incident patients with SLE were identified between 2008 and 2018 using the Korean National Health Insurance databases. Annual direct healthcare costs for five years before and after the diagnosis of SLE were estimated and we compared them with those of age-, sex-, and calendar months-matched controls (1:4). Direct healthcare costs of patients with SLE were compared by disease severity using inverse probability-weighted regression analysis.

**Results** A total of 11,173 incident SLE patients and 45,500 subjects without SLE were identified. Annual direct healthcare costs per person in SLE group was increasing one year before SLE diagnosis, and reached the highest at the first year of SLE diagnosis, resulting 7.7-fold greater than comparators ($5,694 vs. $736 a year, respectively). Among patients with SLE, having severe SLE resulted in 4.39 times (95% CI 1.304–1.623), having comorbidities such as lupus nephritis (1.89 times, 95% CI 1.801–1.983), avascular necrosis (5.482 times, 95% CI 3.977–7.668), chronic kidney diseases (1.783 times, 95% CI 1.601–1.985), and interstitial lung diseases (1.542 times, 95% CI 1.346–1.765) were associated with higher annual direct healthcare costs of the first year.

**Conclusions** Patients with SLE incurred significantly high direct healthcare costs compared to subjects without SLE, especially during the first year after diagnosis. Disease severity as well as comorbidities were associated with increased costs of illness in patients with SLE.

**References**
1. Diaz Fernandez, Daniel Fernandez, John Jaramillo, Alheda Vargas, Carlos Toro. Rheumatology, Organización Sanitaria Internacional, Bogotá, Colombia; 2Rheumatology, Hospital San Ignacio – Pontificia Universidad Javeriana, Bogotá, Colombia; 3Rheumatology, Centro de Referencia en Osteoporosis, Reumatología y Dermatología, Cali, Colombia; 4Rheumatology, Hospital Italiano de Buenos Aires, Argentina; 5Rheumatology, Centro de Referencia en Osteoporosis, Reumatología y Dermatología, Cali, Colombia